Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis

International Journal of Cardiology

Volumn 169, Issue 4, 2013, Pages 262-270

  Savarese, Gianluigi ^a   Rosano, Giuseppe ^b   D'Amore, Carmen ^a   Musella, Francesca ^a   Della Ratta, Giuseppe Luca ^a   Pellegrino, Angela Maria ^a   Formisano, Tiziana ^a   Vitagliano, Alice ^a   Cirillo, Annapaola ^a   Cice, Gennaro ^c   Fimiani, Luigi ^a   Del Guercio, Luca ^a   Trimarco, Bruno ^a   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Angina; Coronary artery disease; Ranolazine

Indexed keywords

ATENOLOL; GLYCERYL TRINITRATE; HEMOGLOBIN A1C; PLACEBO; RANOLAZINE;

ANGINA PECTORIS; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY; EXERCISE TOLERANCE; FUNCTIONAL STATUS; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ST SEGMENT DEPRESSION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANGINA; CORONARY ARTERY DISEASE; RANOLAZINE;

ACETANILIDES; ANGINA PECTORIS; BLOOD PRESSURE; CORONARY ARTERY DISEASE; HEART RATE; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887491765     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.131     Document Type: Article

References (31)

1. R. Holubkov, W.K. Laskey, and A. Haviland Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry Am Heart J 144 2002 826 833
2. W.S. Weintraub, J.A. Spertus, and P. Kolm Effect of PCI on quality of life in patients with stable coronary disease N Engl J Med 359 2008 677 687
3. R.D. Vieira, W. Hueb, and M. Hlatky Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial Circulation 126 2012 S145 S150
4. S.V. Arnold, D.A. Morrow, and Y. Lei Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial Circ Cardiovasc Qual Outcomes 2 2009 344 353
5. S.V. Arnold, D.A. Morrow, and K. Wang Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial Circ Cardiovasc Qual Outcomes 1 2008 107 115
6. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
7. W.E. Boden, R.A. O'Rourke, and K.K. Teo Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med 356 2007 1503 1516
8. B.R. Chaitman Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions Circulation 113 2006 2462 2472
9. D. Moher, A. Liberati, and J. Tetzlaff Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 2009 1006 1012
10. A.S. Detsky, C.D. Naylor, K. O'Rourke, A.J. McGeer, and K.A. L'Abbé Incorporating variations in the quality of individual randomized trials into meta-analysis J Clin Epidemiol 45 1992 255 265
11. G. Savarese, P. Costanzo, and J.G. Cleland A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure J Am Coll Cardiol 61 2013 131 142
12. P. Costanzo, P. Perrone-Filardi, and M. Petretta Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients J Hypertens 27 2009 1136 1151
13. J.P.T. Higgins, J.J. Deeks Chapter 7: selecting studies and collecting data J.P. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions 2011 [(Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane-handbook.org)]
14. S. Sharp, and J. Sterne Meta-analysis STB Rep 7 1998 100 109
15. J.J. Deeks, J.P.T. Higgins, D.G. Altman Chapter 9: Analysing data and undertaking meta-analyses J.P. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions 2011 [Version 5.1.0 (updated March 2011). The Cochrane Collaboration. Available from www.cochrane-handbook.org ]
16. A. Tobias Assessing the influence of a single study in meta-analysis STB 47 1999 15 17
17. S.J. Sharp Meta-analysis regression STB 42 1998 16 22
18. S.G. Thompson, and S.J. Sharp Explaining heterogeneity in meta-analysis: a comparison of methods Stat Med 18 1999 2693 2708
19. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in metaanalysis detected by a simple, graphical test BMJ 315 1997 629 634
20. B.R. Chaitman, S.L. Skettino, and J.O. Parker Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina J Am Coll Cardiol 43 2004 1375 1382
21. B.R. Chaitman, C.J. Pepine, and J.O. Parker Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial JAMA 291 2004 309 316
22. A.D. Timmis, B.R. Chaitman, and M. Crager Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes Eur Heart J 27 2006 42 48
23. M.F. Rousseau, H. Pouleur, G. Cocco, and A.A. Wolff Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris Am J Cardiol 95 2005 311 316
24. P.H. Stone, N.A. Gratsiansky, A. Blokhin, I.Z. Huang, and L. Meng Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial J Am Coll Cardiol 48 2006 566 575
25. D.A. Morrow, B.M. Scirica, and E. Karwatowska-Prokopczuk Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
26. S.R. Wilson, B.M. Scirica, and E. Braunwald Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial J Am Coll Cardiol 53 2009 1510 1516
27. D.A. Morrow, B.M. Scirica, and B.R. Chaitman Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial Circulation 119 2009 2032 2039
28. M. Kosiborod, S.V. Arnold, and J.A. Spertus Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina. Results from the TERISA randomized clinical trial J Am Coll Cardiol 61 2013 2038 2045
29. A.K. Dhalla, D. Liu, M. Santikul, and L. Belardinelli Ranolazine increases glucose-stimulated insulin secretion in-vitro and in-vivo J Am Coll Cardiol 51 2008 A321
30. P. Gargiulo, C. Marciano, and G. Savarese Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries: A digital reactive hyperemia study Int J Cardiol 165 2013 67 71
31. C. Marciano, M. Galderisi, and P. Gargiulo Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease Eur J Nucl Med Mol Imaging 39 2012 1199 1206